The Supervisory Board of Sartorius AG announced today that it has extended the appointment of Dr. René Fáber as a member of the Executive Board by five years, through December 31, 2031. Dr. Fáber, 50, holds a Ph.D. in polymer chemistry from the Technical University of Munich and has been with Sartorius since 2002, initially as a scientist. He assumed his current role overseeing the Bioprocess Solutions Division in January 2019.
This extension signals the company's confidence in Dr. Fáber's leadership amid a dynamic biopharmaceutical landscape. The Bioprocess Solutions Division is a key growth driver for Sartorius, providing single-use solutions for the production of biotech drugs, vaccines, and cell and gene therapies. The division's focus on safer, faster, and more sustainable manufacturing aligns with industry trends toward efficiency and environmental responsibility.
Sartorius, headquartered in Göttingen, Germany, is a leading partner to the biopharmaceutical industry. The company operates through two divisions: Lab Products & Services and Bioprocess Solutions. In 2025, Sartorius generated sales of approximately €3.5 billion, supported by over 14,000 employees at around 60 production and sales sites worldwide. The company regularly enhances its portfolio through strategic acquisitions, as noted in its newsroom.
The extended tenure of Dr. Fáber provides continuity in the executive team, which is crucial as Sartorius navigates post-pandemic shifts in biopharma demand and supply chains. The Bioprocess Solutions Division's innovations in single-use technologies are increasingly critical for reducing contamination risks and speeding up drug development. Industry analysts expect sustained investment in biologics manufacturing, benefiting companies like Sartorius that offer scalable, flexible solutions.
Dr. Fáber's background in polymer chemistry and his long tenure at Sartorius position him well to guide the division's R&D and market expansion. The company's CV of René Fáber highlights his progression through management roles, underscoring his deep understanding of the business.
Investors and stakeholders may view this extension as a positive signal of strategic stability. Sartorius' financial calendar includes upcoming results announcements: first quarter 2026 on April 23, half-year results on July 23, and nine-month results on October 22. These reports will provide further insight into the company's performance under the current leadership.
For more details, the original release is available on NewMediaWire.
